In this issue

More than two years into the pandemic, maintaining a reliable supply chain continues to be a priority for governments and industrial sectors, and any inefficiencies consequently touch people’s lives in one way or another.

In this issue, we took a hard look at the pharmaceutical supply chain by exploring its environmental impact and what happens when it does not work as well as it should. While several pharma companies have pledged to reduce their carbon footprint, they can achieve those goals only if every stakeholder in the process works to make the necessary changes.

The supply and delivery of Covid-19 therapeutics in the US, especially during the surge of cases due to the Omicron variant, provide a great example of how distribution gaps are sometimes exacerbated. In two data-led pieces, we try to correlate the per capita allocations, state populations and Covid-19 case rates to identify places that had the most acute shortages, where better supply planning could have addressed the surge of cases.

Also in this issue, we took a look at the growing research with psychedelics in biotech, both from a research and manufacturing perspective.

All this, and the latest pharma industry news, comment, data and analysis from GlobalData in this issue of Pharmaceutical Technology Focus.

Manasi Vaidya, editor